ARGX-113 Emerging Drug Insight and Market Forecast - 2032

“"ARGX-113 Emerging Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about ARGX-113 for immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the ARGX-113 for ITP in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ARGX-113 for ITP. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ARGX-113 market forecast analysis for ITP in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ITP.

Drug Summary:

Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases and was designed to exploit the natural interaction between IgG antibodies and the recycling receptor FcRn Argenx, designed efgartigimod to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications, namely multiple sclerosis, ITP, systemic lupus erythematosus, myasthenia gravis, and skin-blistering diseases.

Efgartigimod is the Fc-portion of an IgG1 antibody modified by the Argenx proprietary ABDEG technology to increase its affinity for FcRn beyond normal IgG antibodies. As a result, efgartigimod blocks antibody recycling through FcRn binding and leads to fast depletion of the autoimmune disease-causing IgG autoantibodies. The development work on efgartigimod is conducted in close collaboration with Prof. E. Sally Ward (University of Texas Southwestern Medical and Texas A&M University Health Science Center, a part of Texas A & M University (TAMHSC)). The drug is currently in Phase III trial for adult patients with primary ITP.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ARGX-113 description, mechanism of action, dosage and administration, research and development activities in immune thrombocytopenic purpura (ITP).
• Elaborated details on ARGX-113 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ARGX-113 research and development activities in ITP across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ARGX-113.
• The report contains forecasted sales of ARGX-113 for ITP till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ITP.
• The report also features the SWOT analysis with analyst views for ARGX-113 in ITP.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARGX-113 Analytical Perspective by DelveInsight

In-depth ARGX-113 Market Assessment

This report provides a detailed market assessment of ARGX-113 for immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

ARGX-113 Clinical Assessment

The report provides the clinical trials information of ARGX-113 for ITP covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for immune thrombocytopenic purpura (ITP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARGX-113 dominance.
• Other emerging products for ITP are expected to give tough market competition to ARGX-113 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARGX-113 in ITP.
• Our in-depth analysis of the forecasted sales data of ARGX-113 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ARGX-113 in ITP.

Key Questions:

• What is the product type, route of administration and mechanism of action of ARGX-113?
• What is the clinical trial status of the study related to ARGX-113 in immune thrombocytopenic purpura (ITP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARGX-113 development?
• What are the key designations that have been granted to ARGX-113 for ITP?
• What is the forecasted market scenario of ARGX-113 for ITP?
• What are the forecasted sales of ARGX-113 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ARGX-113 for ITP?
• Which are the late-stage emerging therapies under development for the treatment of ITP?